PT3749353T - Nemolizumab no tratamento da dermatite atópica com escoriação moderada a grave - Google Patents

Nemolizumab no tratamento da dermatite atópica com escoriação moderada a grave

Info

Publication number
PT3749353T
PT3749353T PT197104888T PT19710488T PT3749353T PT 3749353 T PT3749353 T PT 3749353T PT 197104888 T PT197104888 T PT 197104888T PT 19710488 T PT19710488 T PT 19710488T PT 3749353 T PT3749353 T PT 3749353T
Authority
PT
Portugal
Prior art keywords
nemolizumab
excoriation
moderate
severe
treatment
Prior art date
Application number
PT197104888T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Chugai Pharmaceutical Co Ltd
Galderma Holding SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65729402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3749353(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Galderma Holding SA filed Critical Chugai Pharmaceutical Co Ltd
Publication of PT3749353T publication Critical patent/PT3749353T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT197104888T 2018-02-09 2019-02-08 Nemolizumab no tratamento da dermatite atópica com escoriação moderada a grave PT3749353T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
PT3749353T true PT3749353T (pt) 2025-10-14

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197104888T PT3749353T (pt) 2018-02-09 2019-02-08 Nemolizumab no tratamento da dermatite atópica com escoriação moderada a grave

Country Status (23)

Country Link
US (2) US12435147B2 (cg-RX-API-DMAC7.html)
EP (2) EP4644424A3 (cg-RX-API-DMAC7.html)
JP (3) JP7777921B2 (cg-RX-API-DMAC7.html)
CN (1) CN112040976A (cg-RX-API-DMAC7.html)
AU (2) AU2019219608B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016144A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002050A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749353T3 (cg-RX-API-DMAC7.html)
ES (1) ES3049513T3 (cg-RX-API-DMAC7.html)
FI (1) FI3749353T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251101T1 (cg-RX-API-DMAC7.html)
IL (1) IL276524A (cg-RX-API-DMAC7.html)
LT (1) LT3749353T (cg-RX-API-DMAC7.html)
MX (1) MX2020008193A (cg-RX-API-DMAC7.html)
PH (1) PH12020551185A1 (cg-RX-API-DMAC7.html)
PL (1) PL3749353T3 (cg-RX-API-DMAC7.html)
PT (1) PT3749353T (cg-RX-API-DMAC7.html)
RU (1) RU2758378C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007558YA (cg-RX-API-DMAC7.html)
SI (1) SI3749353T1 (cg-RX-API-DMAC7.html)
TW (2) TWI856006B (cg-RX-API-DMAC7.html)
WO (1) WO2019155427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535464A (zh) * 2023-11-02 2025-09-16 日商丸寶股份有限公司 醫藥組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
IL276524A (en) 2020-09-30
JP2023182632A (ja) 2023-12-26
EP4644424A3 (en) 2026-01-14
TW202448919A (zh) 2024-12-16
WO2019155427A1 (en) 2019-08-15
CL2020002050A1 (es) 2020-12-11
RU2758378C1 (ru) 2021-10-28
CA3090062A1 (en) 2019-08-15
TWI856006B (zh) 2024-09-21
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
PH12020551185A1 (en) 2021-05-17
HRP20251101T1 (hr) 2025-11-21
JP7777921B2 (ja) 2025-12-01
US20200385476A1 (en) 2020-12-10
SI3749353T1 (sl) 2025-10-30
EP3749353B1 (en) 2025-07-30
TWI923998B (zh) 2026-05-01
JP2025176134A (ja) 2025-12-03
AU2019219608B2 (en) 2025-10-16
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
EP4644424A2 (en) 2025-11-05
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
TW201941800A (zh) 2019-11-01
JP2021512917A (ja) 2021-05-20
US20260008859A1 (en) 2026-01-08
SG11202007558YA (en) 2020-09-29
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
DK3749353T3 (da) 2025-09-01
FI3749353T3 (fi) 2025-09-10
BR112020016144A2 (pt) 2020-12-15
CN112040976A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria for the treatment of disorders
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
PT4327866T (pt) Mirikizumab no tratamento da colite ulcerosa
IL260684B (en) Treatment for modulating gut microbiota
EP4000506C0 (en) CATHETER WITH SUPPORT STRUCTURE HAVING VARIABLE DIMENSIONS
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
DK3127428T3 (da) Anvendelse af forgreningsenzym ec 2.4.1.18 til forbedring af sammenhængskraft i brød
EP3496801A4 (en) DYNAMIC CATHETERIZATION DEVICES CONFIGURED TO FACILITATE DRAINAGE.
HK1215147A1 (zh) 眼部护理装置及方法
MA50879A (fr) Ferme piscicole
EP3658253A4 (en) BIOPOLYMERIC WATER TREATMENT
EP3692155A4 (en) PRODUCTION OF POLYHYDROXYBUTYRATE IN WOOD-LJUNGDAHL MICROORGANISMS
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
PL3727429T3 (pl) Leczenie zaburzeń autonomicznych toksyną botulinową
EP3432901A4 (en) SEQUENTIAL TREATMENT AGAINST CANCER
EP3691601A4 (en) CATHETER WITH BALLOON VALVE
EP3703500A4 (en) ANTIMICROBIAL ORGANIC PRESERVATIVES
LT3405197T (lt) Delgocitinibo panaudojimas lėtinės rankų egzemos gydymui
DK4009942T3 (da) Forbindelse til kombinationsbehandling
IL276524A (en) Nemolizumab for the treatment of atopic dermatitis with moderate to severe itching
IL268732A (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
MX2020000625A (es) Metodos para tratar trastornos microvasculares autoinmunes.
PL3322480T3 (pl) Bakterie Lactobacillus w leczeniu zaburzeń czynności serca
IT201700078353A1 (it) Impianto da bowling.
FR3020452B3 (fr) Module d'etuvage et de conservation, en complement du module d'etuvage en continue